A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
MODERNIZE: A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
Sponsor: Nefro Avillion Clinical Development, LLC
Enrolling: Male and Female Patients
Study Length: 1 Years
IRB Number: ACYY1906
U.S. Govt. ID: NCT07508787
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG). Participants will be followed for 1 year post transplant. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Joshua Weiner, MD
Do You Qualify?
Are you between 18 and 70 years old? Yes No
Are you on the kidney transplant waiting list? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.


For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839